Bristol Myers exits Cellares deal, capacity doubt
Bristol Myers Squibb has ended its partnership with cell therapy manufacturer Cellares, raising questions about standardized production capacity for CAR‑T and forcing a reevaluation of forecasting and capacity planning. In the wake of the deal termination, Cellares is restructuring and cutting jobs as it absorbs the loss of a major customer, underscoring fragility in automated cell therapy manufacturing ecosystems.
Business · 8 sources · Aug 26, 2026Read it
The journal
Open the journal →The conversation starts in the journal — be the first to post.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
Everything about Bristol-Myers Squibb →- Country
- United States
- Headquarters
- New York City
- Inception
- 1989
- Website
- https://www.bms.com/